A systematic review 1 including 3 RCTs with a total of 206 subjects and 2 dose-finding studies with 30 patients in the intervention group was abstracted in DARE. In the dose-related trials oprelvekin showed a trend towards a shorter time to maximum platelet counts and a lower requirement for platelet transfusion with dosages of 25 and 75 µg/kg/day versus 10 µg/kg/day. The combination of oprelvekin and G-CSF appears to accelerate platelet recovery compared to G-CSF alone. In the placebo-controlled trials significantly fewer oprelvekin than placebo recipients required platelet transfusions. The most frequent adverse effects were oedema and dyspnoea.
Comment: The quality of evidence is downgraded by study quality (no discussion of the review's methodological or data limitations).
Primary/Secondary Keywords